More importantly, adult T-ALL patients with DNMT3A mutations have been significantly associated with worse clinical outcomes, a higher cumulative incidence of relapse (HR 2.33, 95% CI: 1.05–5.16, p = 0.037), and markedly poorer event-free survival (HR 3.22, 95% CI: 1.81–5.72, p < 0.001) and overall survival (HR 2.91, 95% CI: 1.56–5.43, p = 0.001) [42]. This evidence concerns the gene DNMT3A and acute lymphoblastic leukemia.